Tuesday, November 24, 2009, 4:42AM AEST - The Australian Stockmarket opens in 5 hours and 18 minutes.
To create a watchlist or portfolio of shares, Register

Amicus Therapeutics, Inc. (FOLD)

 4:25AM AEST: 3.97 USD  Up 0.14 (3.66%)  
 MORE ON FOLD 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Amicus Therapeutics, Inc. (NGM:FOLD) Delayed quote dataEdit
Last Trade:3.97 USD
Trade Time: 4:25AM AEST
Change:Up 0.14 (3.66%)
Prev Close:3.83
Open:3.93
Bid:3.94 x 100
Ask:3.98 x 300
1y Target Est:3.50
Day's Range:3.86 - 4.01
52wk Range:3.68 - 13.50
Volume:22,060
Avg Vol (3m):100,248
Market Cap:89.91M
P/E (ttm):N/A
EPS (ttm):-2.37
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add FOLD to Portfolio   Download Data

 HEADLINES 
•Developments for Parkinson's Disease Ignite Investor Enthusiasm
at Seeking Alpha (Mon, Nov 16)
•Amicus Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
PR Newswire (Fri, Nov 13)
•AMICUS THERAPEUTICS INC Financials
EDGAR Online Financials (Wed, Nov 11)
•AMICUS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Nov 5)
•AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Wed, Nov 4)
•Amicus Therapeutics Appoints Margaret G. McGlynn, R.Ph., to Board of Directors
PR Newswire (Wed, Nov 4)
•Movers roundup: Las Vegas Sands, Monster
AP (Sat, Oct 31)
•Amicus shares fall on closed partnership, job cuts
AP (Sat, Oct 31)
•UPDATE - Amicus Q3 loss narrower than view; ends Shire pact
at Reuters (Fri, Oct 30)
•AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Def
EDGAR Online (Fri, Oct 30)
•Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
PR Newswire (Fri, Oct 30)
More Headlines for FOLD...
 ANALYST 
EPS Est (next year) (Dec-09) :-2.48
EPS Est (in 2 years) (Dec-10) :-2.15
Avg Rec (current)*:3.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs, known as pharmacological chaperones, for the treatment of various human genetic dise...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices